Understanding Non-small Cell Lung Cancer Patient Characteristics, Treatment Patterns and Outcomes

This is a retrospective, cross-sectional, non-interventional, multi-country survey-based chart audit study to evaluate real-world treatment patterns, patient clinical profiles, and clinical outcomes among aNSCLC patients receiving at least 1L SACT in Argentina, Brazil, Mexico, Australia, India, Taiwan, Malaysia, Hong Kong, and Turkey. All patient-level data, including patient demographic and clinical characteristics, treatment history, and clinical outcomes, will be collected retrospectively from existing patient medical records provided by participating physicians, without interference with treatment decisions. Informed consent from individual patients will not be required, as this study describes the analysis of deidentified patient data.

Patient Eligibility Criteria - Inclusion Criteria Diagnosis: Confirmed de novo stage IIIB, IIIC, or IV NSCLC.

Biomarker Status:

Either: EGFR mutation present Or: No actionable gene alterations (AGAs) detected (including EGFR, ALK, ROS1, NTRK, BRAF V600E, RET, MET, KRAS, HER2; patients not tested for these also eligible).

Treatment Start Window: Initiated 1L SACT (systemic anticancer therapy) for advanced NSCLC between the date of first Tagrisso® (osimertinib) approval for NSCLC in their country and 31 December 2024.

Age: 18 years or older at time of 1L SACT initiation.

• Exclusion Criteria Concurrent Malignancies: Patients on active treatment for another primary malignancy at 1L SACT initiation.